ArticleBrain and behavior2026
Selective Anti-Inflammatory Actions of Curcumin on Cytokine Pathways in Major Depressive Disorder.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMajor depressive disorder (MDD) is a prevalent mental illness with a significant disease burden. It is characterized by immune-inflammatory dysregulation.
methodsThis ex vivo study assessed curcumin's immunomodulatory effects in 18 MDD patients and 18 healthy controls (HC). Whole blood samples underwent LPS- and PHA-stimulation to evaluate immune sensitization with curcumin treatment at concentrations of 2, 20, and 200 ng/mL.
resultsMDD patients exhibited marked activation of the immune-inflammatory response system (IRS), M1 macrophages, T helper (Th) 1, growth factors, and chemokine profiles, whereas M2, Th2, and the compensatory immunoregulatory system (CIRS) were less activated, confirming IRS sensitization in MDD. Partial regression analysis confirmed positive correlations between immune biomarkers (e.g., IL-1β) and depression severity scores. In patients with MDD, curcumin selectively and significantly downregulated the overactivated IRS, M1, Th1, and chemokine profiles. Notably, curcumin significantly decreased pro-inflammatory chemokines, such as CCL11, CXCL10, and CCL27, and exhibited inhibitory effects on key inflammatory factors, including TNF-α. Although curcumin did not fully normalize the IRS profiles or significantly affect M2, Th2, or CIRS profiles, its specific inhibition of core inflammatory pathways clearly demonstrates its ability to selectively modulate aberrant immune responses in MDD. Paradoxically, in HC, curcumin showed mild immune-stimulating effects.
conclusionsThese findings demonstrate that curcumin exerts selective anti-inflammatory effects by effectively targeting and suppressing overactivated core inflammatory pathways (e.g., IRS/M1/Th1 and related chemokines) in MDD patients, thereby partially restoring immune homeostasis. This supports the potential role of curcumin as an adjunctive therapeutic strategy for MDD. However, as these findings are derived from an ex vivo model, further in vivo studies are required before clinical recommendations can be made.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.